Section

Science & Medicine

Peer-reviewed research, FDA approvals, psychedelics, neuromodulation, genetics.

Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.

A small, unblinded study with no control group is a reason to run the next trial, not a reason to change anyone's treatment.

A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.

Nov 12 minRead

More in Science & Medicine

219 total in this section

02Science & MedicineNov 1

Doubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?

A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.

03Science & MedicineOct 29

Two Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty

Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.

04Science & MedicineOct 23

Ketamine Is Still a Medicine. A Manchester Detox Ward Shows What Happens When It Stops Being One.

A UK detox unit's 59 ketamine admissions and the ACMD's 2026 review show what dependence looks like when ketamine leaves the clinic. What US providers and people using it should know.

05Science & Medicine

Earlier in Science & Medicine

Every piece in this section, most recent first.

Science & Medicine

Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.

More in Science & Medicine

Doubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?

Two Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty

Ketamine Is Still a Medicine. A Manchester Detox Ward Shows What Happens When It Stops Being One.

24,643 Patients Later, Phenobarbital and Diazepam Look Like a Tie. Don't Rip Up the Protocol Yet.

Hospitals Know How to Prevent a Brain Injury From Drinking. They Keep Giving the Wrong Dose.

Ibogaine Is Being Sold as a Reset Button. Its Own Researchers Say the Evidence Is 'Modest.'

Earlier in Science & Medicine

Doctors Are Writing Fewer Benzodiazepine Prescriptions. The Counterfeits Are Getting Stronger.

Three Hundred and Seventy-One Trials Later, There Is Still No Approved Drug for Meth or Cocaine. The Best Treatment We Have Is a Gift Card.

One Dose Quieted Her Head for Two Hours. Within Weeks She Was Buying More.

Forty-One Approved Addiction Drugs, and Not One for Meth or Cannabis: What the Biggest Medication Review Yet Actually Found

Craving Doesn't Fade the Longer You're Off Opioids. Brain Scans Show It Gets Louder, Then Learns to Hide.

Hopelessness, Not Just Cannabis, Is What Keeps First-Episode Psychosis From Lifting

The FDA Just Made It Easier to Sell Nicotine Pouches. The Drug Meant to Help You Quit Got Turned Away.

A New Study Found the Power Switch Behind Getting High. Turning It Off Is Still Years Away.

The Government Spent 55 Years Calling Psilocybin Medically Worthless. Now It's Racing to Approve It.

A Bladder Clinic for 13-Year-Olds Is What Ketamine's Growth Curve Actually Looks Like

Weed Got Four Times Stronger and Nobody Sent a Memo. The FDA Just Noticed.

The Same Drug Class Reshaping Obesity Medicine Is Now in a Phase 3 Trial for Alcohol Cravings

There's Still No FDA-Approved Pill for Meth or Cocaine Addiction. Here's What Fills the Gap.

Craving Doesn't Break Your Willpower — It Rewrites the Math Your Brain Runs on Every Choice

Benzodiazepines Were Sold as the Safe Pill. Quitting Them Cold Can Still Kill You.

The Weight-Loss Drug Everyone's Talking About Might Also Be the Best Alcohol Medication Nobody's Prescribing

Xylazine Wound Care Has Been Guessing — Two Baltimore Studies Just Asked the Patients Instead

JUUL Is Legal Again — and the FDA's Whole Fix Is a Password Screen

Getting High With Friends Is the Riskier Choice — If You Already Have a Problem

The Craving Doesn't Expire on Your Sobriety Anniversary

Nitrous Oxide Deaths Rose Nearly 600% While Regulators Treated Galaxy Gas Like a Whipped-Cream Ingredient

Dispensary Weed Is a Different Drug Than the One D.A.R.E. Warned You About

The Overdose Charts Miss This: A Decade of Data Says a Third of Alcohol-Induced Crises Come With Depression Attached

Every Two Years, the Fake Xanax Gets a New Name. The Real Trend Is the Naming Pattern Itself.

Your First Ambien Prescription Predicts Whether You're Still Taking It in Seven Years

There's No Suboxone for Meth. The Reason Is in the Chemistry, Not the Funding.

Your Craving Isn't Just a Feeling. Yale Says It's Rewiring How You Decide, in Real Time.

The FDA Finally Wrote Rules for Psychedelic Trials. Now It Wants to Hear If They're Any Good.

Relapse Isn't a Willpower Failure. Two New Studies Say It's Math the Brain Never Stopped Running.

The FDA Is Finally Asking the Public What It Thinks About Psychedelic Therapy. That Question Was Illegal to Even Study for 40 Years.

Ketamine Works Because It Unmoors You From Yourself — And Almost Nobody Is Watching How It's Sold

Banning Xylazine Didn't Shrink the Tranquilizer Supply. It Just Renamed the Problem Medetomidine.

The Same Drug Class Behind Ozempic Is Now the Most Promising Alcohol Medication in 20 Years

The Cannabis Red Flag Isn't How Often. It's How Many Ways.

The Feds Are Scheduling Three New Drugs at Once. The Chemists Are Already on a Fourth.

Psilocybin Just Got the FDA's Fastest Lane Ever Built. Getting There Is Still the Hard Part.

A Brain Region Lights Up Before Relapse Happens, Mouse Study Suggests

MDMA Therapy's Second Shot at FDA Approval Skips the One Thing That Sank It Last Time

The Wine Study Measured Wealth, Not Wine

American Drinking Just Hit a Historic Low — Because the 'Healthy Glass of Wine' Myth Finally Died

Cannabis Use Disorder Just Passed Alcohol in America — and Emergency Rooms Are Already Catching the Bill

Alcohol Use Disorder Is Finally Falling. Cannabis Use Disorder Is Climbing to Take Its Place.

Oregon Has Run the Largest Real-World Psilocybin Experiment on Earth. The First Full Results Are In.

Cannabis Didn't Get Safer Than Alcohol — the Evidence Against It Just Got Sharper

The Psilocybin Lab Left the Building — Two New Studies Show What Happens Next

Semaglutide Just Outperformed Every FDA-Approved Alcohol Medication. It's Still Not Approved For That.

A Brain Scan Just Showed What Mindfulness Actually Does to a Craving

The VA Just Bet on Ozempic for Alcoholism — Because No One Ever Built Alcoholism a Drug of Its Own

Ketamine Is Becoming Medicine and Contraband at the Same Time

The Math on Cutting Syringe Funding: Up to 39,600 Extra Deaths

FDA Fast-Tracks an Ozempic-Class Drug for Alcohol Use Disorder

A Fentanyl Vaccine Is in Human Trials. It Is Not Ready to Save Anyone Yet.

Your Brain Doesn't Just Feel a Craving. A Craving Changes How Your Brain Decides.